eHandbook: Supply Chain

Geopolitical and economic uncertainty remain formidable challenges for the pharmaceutical industry, which this year weathered a volatile global business environment. The sector in 2026 continued to face manufacturing and supply chain risks, requiring agility and flexibility in companies’ operational strategies.

Tariffs are increasing costs for ingredients, raw materials, and lab supplies, causing companies to take steps to reduce exposure with U.S. investment while keeping global networks intact. Rather than fully reshoring, many firms are hedging against policy shifts and tariff volatility by adding domestic capacity and maintaining trusted overseas partners.

This eHandbook examines the business dynamics of having both U.S. and global capacity and creating hybrid models that balance resilience, cost, and regulatory complexity.